Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Federal Antimonopoly Service approves the cost of blocking the formation of blood clots generic
- By Newsdesk
- Russia
- Jun 08, 2023
Federal Antimonopoly Service (FAS) has set the price for the drug (MP) "Axartoban" (dabigatran etexilate), an analogue of Boehringer Ingelheim's "Pradaksa."
A package of 30 "Axartoban" capsules will cost no more than 1241.18 rubles, which is 20% less than the original drug's price (1634.86 rubles).
The Russian drug has been designated as the second domestic generic of dabigatran etexilate. First, Dabiksom entered the market, and now that prices for the second analogue have been registered, the cost of the first one should be reduced by more than 10%. "The agency will send a corresponding notification to the pharmaceutical manufacturer," according to the FAS.
On the same day, the Federal Antimonopoly Service reached an agreement on a price for the domestic anthelmintic drug Praziquantel. In the Russian Federation, this is the first analogue of the foreign "Biltricide" from Bayer.